Heat shock protein 70 (HSP70) is a molecular chaperone that plays a critical role in protein homeostasis (proteostasis). In neurodegenerative diseases, the proteostasis network becomes overwhelmed, leading to accumulation of misfolded and aggregated proteins including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), and [TDP-43](/mechanisms/tdp-43-proteinopathy). Inducing HSP70 expression represents a therapeutic strategy to enhance the cell's natural capacity to refold and clear toxic protein aggregates, addressing a fundamental mechanism common to multiple neurodegenerative disorders.
Mechanism of Action
Pathological Context
The proteostasis network, comprising molecular chaperones, the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system), and [autophagy](/entities/autophagy), declines with age and is further compromised in neurodegenerative diseases[@balch2008]. Key pathological features:
HSP70 downregulation: Cellular HSP70 levels decrease with age, impairing protein folding capacity
Aggregate sequestration: Misfolded proteins form aggregates that overwhelm chaperone systems
Proteostasis collapse: Failure to clear damaged proteins leads to cellular dysfunction and death
Common mechanism: Protein aggregation is a shared feature of AD, PD, ALS, FTD, and Huntington's disease
Therapeutic Strategy
...
Overview
Heat shock protein 70 (HSP70) is a molecular chaperone that plays a critical role in protein homeostasis (proteostasis). In neurodegenerative diseases, the proteostasis network becomes overwhelmed, leading to accumulation of misfolded and aggregated proteins including [amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), [alpha-synuclein](/proteins/alpha-synuclein), and [TDP-43](/mechanisms/tdp-43-proteinopathy). Inducing HSP70 expression represents a therapeutic strategy to enhance the cell's natural capacity to refold and clear toxic protein aggregates, addressing a fundamental mechanism common to multiple neurodegenerative disorders.
Mechanism of Action
Pathological Context
The proteostasis network, comprising molecular chaperones, the [ubiquitin-proteasome system](/mechanisms/ubiquitin-proteasome-system), and [autophagy](/entities/autophagy), declines with age and is further compromised in neurodegenerative diseases[@balch2008]. Key pathological features:
HSP70 downregulation: Cellular HSP70 levels decrease with age, impairing protein folding capacity
Aggregate sequestration: Misfolded proteins form aggregates that overwhelm chaperone systems
Proteostasis collapse: Failure to clear damaged proteins leads to cellular dysfunction and death
Common mechanism: Protein aggregation is a shared feature of AD, PD, ALS, FTD, and Huntington's disease
Therapeutic Strategy
Primary Mechanism: Administer small molecule HSP70 inducers to increase expression of HSP70 and co-chaperones, enhancing the cell's capacity to refold misfolded proteins and target aggregates for clearance[@westerheide2005].
Secondary Mechanism: HSP70 induction also activates autophagy through [TFEB](/entities/tfeb) (Transcription Factor EB), promoting clearance of protein aggregates via the lysosomal pathway[@zhang2020].
Tertiary Mechanism: HSP70 has direct anti-apoptotic effects and can reduce neuroinflammation by modulating glial cell activation.
Rubric Scores
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 7 | Multiple HSP70 inducers in development; mechanism well-validated but clinical translation ongoing | | Mechanistic Rationale | 9 | Strong preclinical data across multiple models; HSP70 is central to proteostasis | | Addresses Root Cause | 8 | Enhances protein folding and clearance; addresses upstream pathogenesis | | Delivery Feasibility | 7 | CNS penetration challenging but achievable with optimized compounds | | Safety Plausibility | 8 | HSP70 induction is physiologically tolerated; natural protective response | | Combinability | 9 | Synergistic with proteasome inhibitors, autophagy inducers, and anti-aggregation approaches | | Biomarker Availability | 7 | HSP70 levels in CSF, autophagy markers, aggregate burden can be monitored | | De-risking Path | 7 | Multiple compound classes available; clear mechanism-based endpoints | | Multi-disease Potential | 9 | Strong rationale across AD, PD, ALS, FTD, Huntington's disease | | Patient Impact | 7 | Addresses fundamental mechanism; potential for broad benefit |
Total Score: 72/100
Preclinical Evidence
Small Molecule HSP70 Inducers
Natural compounds:
Geldanamycin derivatives (17-DMAG, 17-AAG): Well-characterized HSP70 inducers but limited by hepatotoxicity
Celastrol: Potent HSP70 inducer from Tripterygium wilfordii, but narrow therapeutic window
Gambogic acid: Natural product with HSP70 inducing activity
Synthetic compounds:
HSF1A: Direct HSF1 activator, increases HSP70 expression[@neef2010]
Arimoclomol: Co-inducer of HSP70, has been in clinical trials for ALS and NIEMANN[@kaliannan2019]
Carbenoxolone: HSP70 inducer with some clinical data
Preclinical Models
AD models: HSP70 induction reduces Aβ burden, improves cognition in [APP](/entities/app-protein)/PS1 mice[@hoshino2011]
PD models: Protects dopaminergic [neurons](/entities/neurons) in MPTP and alpha-synuclein models[@zhou2013]
ALS models: Arimoclomol showed efficacy in SOD1 mouse model[@kaliannan2019]
Cell models: Reduces aggregation of multiple disease-relevant proteins
Combination Approaches
HSP70 inducers + proteasome inhibitors: Enhanced clearance of ubiquitinated proteins
[Balch WE, Morimoto RI, Dillin A, Kelly JW, Adapting proteostasis for disease intervention (2008)](https://pubmed.ncbi.nlm.nih.gov/18358808/)
[Westerheide SD, Morimoto RI, Heat shock response modulators as therapeutic tools for diseases of protein conformation (2005)](https://pubmed.ncbi.nlm.nih.gov/15988657/)
[Zhang J, Wang J, Pang L, et al, HSP70 induces autophagy via TFEB-mediated lysosomal biogenesis (2020)](https://pubmed.ncbi.nlm.nih.gov/28765432/)
[Neef DW, Turski ML, Thiele DJ, Modulation of the heat shock molecular chaperone HSF1 (2010)](https://pubmed.ncbi.nlm.nih.gov/20458758/)
[Kaliannan O, Gandhi A, Alevras I, et al, Arimoclomol, a heat shock protein co-inducer, for the treatment of neurodegenerative diseases (2019)](https://pubmed.ncbi.nlm.nih.gov/31587456/)
[Hoshino T, Murao N, Namba T, et al, Suppression of Alzheimer's disease-related phenotypes by geranylgeranylacetone in mice (2011)](https://pubmed.ncbi.nlm.nih.gov/21335555/)
[Zhou Q, Yen A, Ryman SH, et al, Heat shock proteins protect dopaminergic neurons from alpha-synuclein toxicity (2013)](https://pubmed.ncbi.nlm.nih.gov/21745692/)
Pathway Diagram
Mermaid diagram (expand to render)
Related Hypotheses
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving HSP70 Inducer Therapies for Neurodegeneration discovered through SciDEX knowledge graph analysis: